The Diabetes Prevention Program randomized participants at high risk of T2D (based on impaired glucose tolerance, an elevated fasting glucose and overweight) to placebo, metformin, or intensive lifestyle modification. Both the metformin and lifestyle interventions proved effective in preventing or delaying the onset of diabetes [DPP NEJM paper], and these effects were sustained [DPP Lancet paper]. Dr. Florez leads the genetics initiative in the DPP, where extensive physiological characterization of genetic loci and the interaction between genetic background and diabetes preventive interventions can be assessed.
